SH2 domain inhibition: a problem solved? (Q34318063)

1 August 2017

1 reference

title

SH2 domain inhibition: a problem solved? (English)

1 reference

1 August 2017

Shakespeare WC

1

1 reference

1 August 2017

1 August 2001

1 reference

Current Opinion in Chemical Biology

1 August 2017

1 reference

1 August 2017

5

1 reference

1 August 2017

4

1 reference

1 August 2017

409-415

1 reference

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

c-Src, receptor tyrosine kinases, and human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Src homology-2 domains: structure, mechanisms, and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Progress in the development of inhibitors of SH2 domains

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

SH2 domains recognize specific phosphopeptide sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design and synthesis of a novel class of Src SH2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-activity relationships of a novel class of Src SH2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural study

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

The formation of a covalent complex between a dipeptide ligand and the src SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

An efficient synthesis of a 4'-phosphonodifluoromethyl-3'-formyl-phenylalanine containing SRC SH2 ligand.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

SH2 and SH3 domains: potential targets for anti-cancer drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

SH2/SH3 signaling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Highly potent inhibitors of the Grb2-SH2 domain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2800%2900222-2

7 January 2021

10.1016/S1367-5931(00)00222-2

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11470604